HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Quantitative microhaemagglutination assay for Treponema pallidum antibodies in experimental syphilis.

Abstract
The quantitative microhaemagglutination assay for Treponema pallidum antibodies (MHA-TP) was studies in 52 untreated and treated rabbits with experimental syphilis. Rabbits with incubating experimental syphilis were cured or inadequately treated with penicillin G and some cured rabbits were later reinfected. MHA-TP conversion occurred within 45 days in untreated rabbits. Titres reached peak levels about four months after inoculation and remained relatively high for up to two years. The quantitative MHA-TP test differentiated between rabbits cured of experimental incubating syphilis and those untreated and inadequately treated. MHA-TP titres decreased after treatment given six or 12 months after inoculation but reversion did not occur. MHA-TP conversion or significant increases in titre occurred as soon as seven days after reinfection and preceded corresponding changes in a quantitative non-treponemal test. The MHA-TP is useful as a screening test for treponemal antibodies in rabbits. The quantitative MHA-TP in humans after treatment for syphilis and reinfection deserves further study.
AuthorsR R Tight, A C White
JournalThe British journal of venereal diseases (Br J Vener Dis) Vol. 56 Issue 5 Pg. 291-6 (Oct 1980) ISSN: 0007-134X [Print] England
PMID7000307 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bacterial
  • Penicillin G Benzathine
Topics
  • Animals
  • Antibodies, Bacterial (analysis)
  • Hemagglutination Tests (methods)
  • Male
  • Penicillin G Benzathine (therapeutic use)
  • Rabbits
  • Syphilis (drug therapy, immunology)
  • Syphilis Serodiagnosis (methods)
  • Time Factors
  • Treponema pallidum (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: